Dominari Holdings, Inc.

As of November 6, 2023, Dominari Holdings, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 1.87 and a troubling ROCE of -169.94%, with its stock price of 6.33 significantly below its 52-week high of 13.58.

As of June 2, 2025, Dominari Holdings, Inc. shows a mildly bullish trend driven by monthly bullish MACD and KST indicators, though conflicting weekly signals suggest mixed conditions.

As of November 6, 2023, Dominari Holdings, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 1.87 and a significantly negative Return on Capital Employed of -169.94%, despite strong year-to-date stock returns of 451.61%.

As of March 2022, the management team of Dominari Holdings, Inc. includes Dr. Robert Vander Zanden (Independent Chairman), Mr. Anthony Hayes (CEO and multiple officer roles), and Directors Mr. Robert Dudley, Mr. Gregory Blattner, Mr. Tim Ledwick, and Mr. Paul LeMire. The team features a blend of executive leadership and independent directors.

Dominari Holdings, Inc. is a biotechnology company focused on developing small-molecule anti-cancer therapeutics. As of March 2025, it reported net sales of $8 million and a net loss of $32 million, with a market cap of $74.11 million.

As of Jun 18, Dominari Holdings, Inc. has a market capitalization of 74.11 million and reported net sales of 24.88 million, with a net profit loss of 41.75 million over the latest four quarters. Shareholder's funds are at 39.85 million, and total assets are 48.01 million.